Benralizumab for severe eosinophilic asthma in Italy
Treatments studied
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This study follows people with severe eosinophilic asthma who are starting benralizumab. It looks at how well the treatment works in real life, outside of a controlled research setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have severe asthma that is not well controlled and is linked to high eosinophil levels
- Your doctor has decided to prescribe benralizumab according to the standard guidelines
- You haven't taken benralizumab in the past year
- You are not currently taking other biologic asthma medicines like omalizumab or mepolizumab
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to take asthma medicine using a device that tracks your inhaler use. If you already use Fasenra (benralizumab) for severe asthma, you may be able to join.
This study looks at people in China with severe eosinophilic asthma who are starting a new medicine called benralizumab. It will collect information about their symptoms and quality of life to understand who benefits most.
This study tests if adding a new injectable medicine (benralizumab) to your current medium-dose inhaler works better than simply increasing your inhaler dose to control hard-to-treat asthma. It may help people with a specific type of asthma linked to high eosinophil levels.
This study is for people with severe eosinophilic asthma who are about to start a medicine called Benralizumab (Fasenra). It will observe how the medicine works in real life, and requires you to answer some questions about your asthma every week and month.
This trial lets people who completed an earlier benralizumab study and are benefiting from the medicine keep receiving it. The goal is to provide ongoing access while we continue to monitor safety and effectiveness.
This trial studies whether a specific “signature” from asthma tests can predict who will respond to benralizumab (a severe asthma biologic). If you qualify, the researchers will compare your test results to how well benralizumab controls your asthma and prevents flare-ups.
Hear when a new Severe Eosinophilic Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.